Videos de Experimentos Relacionados
Resumen
No abstract available in PubMed .
Videos de Conceptos Relacionados
También podría leer
Artículos Relacionados
Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.
Ordenar por
Same author
Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.
Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author
Prospective Longitudinal Assessment of Quality of Life After Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-based SABR-5 Phase II Trial.
Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author
Validation of the Prognostic Utility of ESTRO/EORTC Oligometastatic Disease Classification: A Secondary Analysis From the Population-Based Phase II SABR-5 Trial.
International journal of radiation oncology, biology, physics·2022
Same author
Combined Radiotherapy and New Systemic Therapies - Have We Moved Beyond Palliation?
Clinical oncology (Royal College of Radiologists (Great Britain))·2020
Same author
An initial melanoma diagnosis may increase the subsequent risk of prostate cancer: Results from the New South Wales Cancer Registry.
Scientific reports·2018
Same author
An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high?
World journal of urology·2015
Same journal
Rethinking anticoagulation intensity during extracorporeal membrane oxygenation.
Lancet (London, England)·2026
Same journal
Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial.
Lancet (London, England)·2026
Same journal
Inherited retinal degenerations: clinical phenotypes and emerging therapies.
Lancet (London, England)·2026
Same journal
Assisted dying and the silencing of medicine's next generation.
Lancet (London, England)·2026